## **Resource Summary Report**

Generated by NIF on Apr 26, 2025

# **Simulx**

RRID:SCR\_000486

Type: Tool

### **Proper Citation**

Simulx (RRID:SCR\_000486)

#### **Resource Information**

**URL:** http://www.ddmore.eu/simulx

Proper Citation: Simulx (RRID:SCR\_000486)

**Description:** THIS RESOURCE IS NO LONGER IN SERVICE. Documented on April 8, 2025. R function for computing predictions and simulating data from both Mlxtran and PharmML models that is based on MlxCompute, the model simulation engine developed by Lixoft. MlxCompute combines the Mlxtran language interpreter with the equation solvers to compute efficiently complex systems of ordinary differential equations (ODEs) and delayed differential equations (DDEs). Simulx takes advantage of the modularity of hierarchical models for simulating different components of a model: models for population parameters, individual covariates, individual parameters and longitudinal data, including continuous, count, categorical, and time-to-event data. It is also extremely flexible for defining complex dose regimens. Simulx will be the core of the next version of the DDMoRe Clinical Trial Simulator.

**Abbreviations:** Simulx

**Resource Type:** software resource

**Keywords:** windows, linux, macos, model, r, simulation, population, covariate, dose regimen

**Funding:** 

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: Simulx

Resource ID: SCR\_000486

Alternate IDs: nlx\_158166

License: CeCILL-B license

**Record Creation Time:** 20220129T080201+0000

**Record Last Update:** 20250420T013951+0000

### **Ratings and Alerts**

No rating or validation information has been found for Simulx.

No alerts have been found for Simulx.

#### Data and Source Information

Source: SciCrunch Registry

## **Usage and Citation Metrics**

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at NIF.

Dinh TD, et al. (2022) Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-III Patients. Infection and drug resistance, 15, 4575.

Nguyen TM, et al. (2021) Population Pharmacokinetics and Dose Optimization of Ceftazidime and Imipenem in Patients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Pharmaceutics, 13(4).